



Foldamers as Protein Mimics ¶ <u>Gilles Guichard1</u> ¶ ¹Univ. Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248,

Institut Européen de Chimie et Biologie, F-33607 Pessac

The discovery that synthetic sequence-specific oligomers can adopt well-defined folded structures – foldamers^[1] – has profoundly changed our view of biopolymer mimicry, raising prospects for exploring new chemical spaces and creating novel synthetic architectures with defined functions.^[2] In this presentation, we will discuss some of our efforts towards this goal, showing how de novo design, careful structural investigation and subsequent sequence engineering of non-peptide helical foldamers may be used to generate effective peptide and protein mimics.

Besides aliphatic and aromatic oligoamide foldamers (β -peptides, peptoids, sulfono- γ -AApeptides, quinoline-based oligoamides,...) which have received much of the attention in the field, a few other backbones that do not contain an amide linkage but similarly show a high folding propensity (*e.g.* aliphatic urea-based oligomers studied in our group) have emerged. Oligourea foldamers which form well-defined and stable helical secondary structures reminiscent of the α -helix combine a number of characteristics – synthetic accessibility, sequence modularity, folding fidelity, and stability to proteolysis – that bode well for their use in various applications. Moreover, it was recently recognized that this synthetic helical backbone can be interfaced with regular α -peptides to generate helically folded peptide-oligourea hybrids that display additional features in terms of helix mimicry and protein-surface recognition properties.^[3]

Applications developed in our group with a focus on molecular recognition include the design of (*i*) bioactive peptide mimics with a reduced peptide character and improved pharmacological properties (*i.e.* modulators of protein-protein interactions and receptor ligands); (*ii*) composite proteins; (*iii*) protein-like quaternary structures and (*iv*) foldamer-based organocatalysts.

References:

[3] Yoo, S. H.; Li, B.; Dolain, C.; Pasco, M.; Guichard, G.: Chapter Three - Urea based foldamers. In *Methods Enzymol.*; Petersson, E. J., Ed.; Academic Press, **2021**; Vol. 656; pp 59-92.

^[1] Gellman, S. H. Foldamers: A Manifesto. Acc. Chem. Res. **1998**, 31, 173-180.

^{[2] (}a) Guichard, G.; Huc, I. Synthetic foldamers. *Chem. Commun.* **2011**, *47*, 5933-5941. (b) Gopalakrishnan, R.; Frolov, A. I.; Knerr, L.; Drury, W. J.; Valeur, E. Therapeutic Potential of Foldamers: From Chemical Biology Tools To Drug Candidates? *J. Med. Chem.* **2016**, *59*, 9599-9621. (c) Pasco, M.; Dolain, C.; Guichard, G.: Foldamers in Medicinal Chemistry. In *Comprehensive Supramolecular Chemistry II*; Atwood, J. L., Ed.; Elsevier: Oxford, **2017**; Vol. 5; pp 89–125. (d) Pasco, M.; Dolain, C.; Guichard, G.: Foldamers. In *Supramolecular Chemistry in Water*; Kubik, S., Ed.; Wiley-VCH Verlag GmbH & Co. KGaA Weinheim, Germany, **2019**; pp 337-374. (e) Girvin, Z. C.; Gellman, S. H. Foldamer Catalysis. *J. Am. Chem. Soc.* **2020**, *142*, 17211-17223. (f) Horne, W. S.; Grossmann, T. N. Proteomimetics as protein-inspired scaffolds with defined tertiary folding patterns. *Nat. Chem.* **2020**, *12*, 331-337.